Treatment-resistant depression

…and machine learning to study treatment-resistant depression. The conversation examines biomarkers of recovery, open- and closed-loop interventions, prediction of treatment responses and explainable models, while addressing the obstacles and interdisciplinary work involved in precision neuroengineering.

Serotonergic psychedelics are emerging as alternative therapies for treatment-resistant depression; however, their hallucinogenic effects may limit their widespread clinical use. Second-generation psychedelics, which lack hallucinogenic effects, are a promising alternative. 2-Bromo-LSD (2-Br-LSD/BETR-001) is an LSD derivative with 5-HT2A partial agonist activity that lacks hallucinogenic effects. Thus, 2-Br-LSD may represent a possible novel therapeutic for treating neuropsychiatric diseases. We assessed the effects of 2-Br-LSD on stress-coping behaviour in mice, using the forced swim test, an

Treatment-resistant depression is a global public health concern, leaving a significant portion of the population without effective remedies. To address this issue, innovative strategies are urgently needed. Psilocybin, a non-selective 5-HT2AR agonist, has been found to alleviate depressive mood in individuals with treatment resistant depression (Carhart-Harris et al., 2017) Ketamine exhibits robust and enduring antidepressant properties both in patients and preclinical models. (Krystal et al., 2013). Sleep patterns are often affected by depressive disorders, making wireless EEG a valuable too

Treatment-resistant depression is a global public health concern, leaving a significant portion of the population without effective remedies. To address this issue, innovative strategies are urgently needed. Psilocybin, a non-selective 5-HT2AR agonist, has been found to alleviate depressive mood in individuals with treatment resistant depression (Carhart-Harris et al., 2017) Ketamine exhibits robust and enduring antidepressant properties both in patients and preclinical models. (Krystal et al., 2013). Sleep patterns are often affected by depressive disorders, making wireless EEG a valuable

Depression affects 20% of the general population and is a leading cause of disability worldwide, with one third of patients presenting treatment-resistant depression (TRD). Subanesthetic ketamine is a promising rapid-acting TRD pharmacotherapy, but optimal treatment frequency remains unclear. The present study aims to better understand the effects of an acute (single dose) and chronic (one week daily) 10mg/kg ketamine treatment on hippocampal plasticity, a key mechanism impaired in depression, in a putative TRD model: the Wistar-Kyoto (WKY) rat exposed to chronic mild stress (CMS). Rats were e

Treatment-resistant depression (TRD), which refers poor responses to adequate antidepressant treatment, have prominent cognitive impairment. Moreover, the depression patients with cognitive impairment could be a risk factor for dementia following aging. The lower aminobutyric acid type A receptor (GABAAR)-mediated activity and GABAB receptor (GABABR)-mediated activity was observed in prefrontal cortex (PFC) of patients with depression. Furthermore, the concentrations declined of both GABA in the PFC following the aging and at beginning of the mid-age has been found, suggesting the GABAergic sy

…as a promising intervention for treatment-resistant depression. Our study systematically investigated the NA system in a depression model and explored the modulatory effects of mfb-DBS on this system.Using Flinders Sensitive Line (FSL) rats as a depression model and Sprague Dawley (SD) rats as controls, we examined the spatial distribution and myelination of NA fibers within the mfb under confocal microscopy, monitored real-time in vivo NA release in response to mfb-DBS in the mPFC and NAC during 6 different s

…neuromodulation treatment for treatment-resistant depression. Mustafa Husain, MD, is an adjunct professor of Psychiatry and Behavioral S

…global burden of disease, and by 2030, depression alone will be the leadingcause of disability around the world – outpacing heart disease, cancer, and HIV. This grim pictureis further compounded by the mental health burden delivered by the coronavirus pandemic.The lack of novel treatment options in psychiatry is restricted by a limited understanding in theneuroscience basis of mental disorders, availability of relevant biomarkers, poor predictability inanimal models, and high failure rates